title: Management of osteoporosis with calcitriol in elderly Chinese patients: a systematic review.
abstract: Osteoporosis, a skeletal disorder characterized by a reduction in bone strength, is becoming a major public health problem in the People's Republic of China, with a rapid increase observed among the population. Chinese guidelines particularly recommend use of active vitamin D in managing osteoporosis. 1,25-(OH)2D3 (calcitriol) is an active vitamin D metabolite. It plays a role in many biological processes, especially in bone metabolism and muscle function, and is mediated by vitamin D receptors. Osteoporosis in elderly men and women is characterized by uncoupled bone remodeling, which is induced by sex hormone deficiencies, somatopause, vitamin D deficiency, reduced synthesis of D hormone, and lack of receptors or receptor affinity for D hormone in target organs. Reviewed here are six randomized controlled trials on calcitriol monotherapy and five on calcitriol therapy combined with other antiosteoporotic agents. Evidence from these trials shows that calcitriol monotherapy can improve bone mineral density in elderly osteoporotic Chinese patients but may be insufficient for long-term treatment. Calcitriol can also decrease bone turnover markers and bring about significant improvements in muscle strength. Further, calcitriol in combination with other therapeutic bone agents was shown to be well tolerated and capable of additional bone-preserving effects compared with use of calcitriol alone in areas including bone mineral density, bone turnover markers, bone pain improvement, and fracture incidence. Hypercalcemia and hypercalciuria, the most common side effects of calcitriol therapy, were not documented in the trials reviewed, and might have been the result of the low dosages used. One study showed that treatment with calcitriol can improve quality of life in patients with osteoporosis, although not to the same extent as bisphosphonates.
authors.affiliation: Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Ruo-xi
authors.initials: RX
authors.lastname: Liao
authors.affiliation: Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Miao
authors.initials: M
authors.lastname: Yu
authors.affiliation: Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
authors.forename: Weibo
authors.initials: W
authors.lastname: Xia
mesh_terms: D000368:Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use*; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D053580:Muscle Strength / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics
chemical_list: D050071:Bone Density Conservation Agents; D018167:Receptors, Calcitriol; C579457:VDR protein, human; D002117:Calcitriol
keywords: calcitriol; osteoporosis; review; vitamin D; vitamin D receptor
references.citation: Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):543-59
references.pmid: 21872797
references.citation: Osteoporos Int. 2010 Jul;21(7):1133-49
references.pmid: 19960185
references.citation: Acta Pharmacol Sin. 2009 Mar;30(3):372-8
references.pmid: 19262561
references.citation: Exp Cell Res. 2002 Apr 1;274(2):323-33
references.pmid: 11900492
references.citation: Nutrients. 2010 Sep;2(9):997-1004
references.pmid: 22254068
references.citation: Arch Gerontol Geriatr. 2011 May-Jun;52(3):e106-9
references.pmid: 21036408
references.citation: J Bone Miner Res. 1997 Dec;12(12):2082-8
references.pmid: 9421241
references.citation: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10529-34
references.pmid: 9724737
references.citation: Steroids. 2001 Mar-May;66(3-5):381-9
references.pmid: 11179747
references.citation: J Clin Endocrinol Metab. 1992 Jul;75(1):176-82
references.pmid: 1320048
references.citation: Biochem Biophys Res Commun. 1997 Oct 20;239(2):562-5
references.pmid: 9344870
references.citation: Mol Cell Endocrinol. 1995 Oct 30;114(1-2):1-8
references.pmid: 8674833
references.citation: Pflugers Arch. 2011 Jan;461(1):77-90
references.pmid: 21057807
references.citation: J Clin Invest. 1975 Nov;56(5):1100-7
references.pmid: 1184737
references.citation: Cell Signal. 1994 Sep;6(7):717-24
references.pmid: 7888298
references.citation: N Engl J Med. 1989 Feb 2;320(5):277-81
references.pmid: 2911322
references.citation: Pharmacogenet Genomics. 2005 Feb;15(2):127-35
references.pmid: 15861036
references.citation: Calcif Tissue Int. 1993 Feb;52(2):146-8
references.pmid: 8443691
references.citation: J Clin Endocrinol Metab. 1997 Jan;82(1):260-4
references.pmid: 8989271
references.citation: Am J Obstet Gynecol. 1999 May;180(5):1115-20
references.pmid: 10329864
references.citation: Bone. 2003 Apr;32(4):397-404
references.pmid: 12689683
references.citation: Am J Clin Nutr. 2002 Apr;75(4):611-5
references.pmid: 11916748
references.citation: Calcif Tissue Int. 1999 Oct;65(4):317-27
references.pmid: 10485985